AbbVie
ABBV Mega CapHealthcare · Drug Manufacturers - General
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face;
AbbVie Stock at a Glance
AbbVie (ABBV) is currently trading at $212.32 with a market capitalization of $375.1B. The trailing P/E ratio stands at 104.59x, with a forward P/E of 13.08x. The 52-week range spans from $180.25 to $244.81; the current price is 13.3% below the yearly high. Year-over-year revenue growth stands at +12.4%. The net profit margin stands at 5.79%.
💰 Dividend
AbbVie pays an annual dividend of $6.92 per share, representing a yield of 3.26%. The payout ratio stands at 325.98%. The elevated payout ratio reflects a mature dividend policy.
📊 Analyst Rating
29 analysts rate AbbVie (ABBV) on consensus: Buy. The average price target is $252.90, implying +19.11% from the current price. Analyst price targets range from $184.00 to $328.00.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 72.03% — indicates pricing power
- Analyst consensus: Buy
- Solid dividend yield of 3.26%
- Positive free cash flow
- –High valuation multiple (P/E 104.59x)
- –Currently flagged as overvalued
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
AbbVie 2026: Humira Cliff Is Behind, Skyrizi + Rinvoq at $30B Combined Run-Rate — the Pharma Compounder Few Believe In
The Real Story
AbbVie closed May 12, 2026 at $202.85 — recovering 15% off the August 2024 low of $176 but still 17% below the all-time high of $244. The $358B market cap places AbbVie as the 5th-largest US pharma. The 2026 thesis is the cleanest story in big pharma: Humira (formerly 60% of revenue) is now 11% as biosimilars erode the franchise — yet total revenue grew +12.4% in Q1/2026 because Skyrizi and Rinvoq combined hit $7.4B in a single quarter, a $30B annualized run-rate.
The Humira-to-successors transition is the rarest thing in pharma history: a successful patent-cliff navigation without revenue collapse. AbbVie peaked at $58B Humira revenue in 2022; 2025 Humira revenue dropped to $9.4B. The simultaneous Skyrizi + Rinvoq ramp from $7.7B (2022) to $30B+ (2026 run-rate) more than offset the loss. Q1/2026 Skyrizi: $4.2B (+27% YoY), Rinvoq: $3.2B (+38% YoY). Combined trajectory: $33B by end-2026, $40B+ by 2028 — bigger than Humira ever was.
The pipeline beyond Skyrizi/Rinvoq is what makes 2026 interesting. Vraylar (depression/schizophrenia) at $4.1B run-rate, Botox cosmetic and therapeutic at $6B combined, the Cerevel acquisition (Parkinson's, schizophrenia pipeline) closed August 2024 adds $4B+ peak revenue potential. The Q1/2026 EPS GAAP -46.2% is misleading — it includes Cerevel acquisition charges and divestiture losses; adjusted operational EPS was +8.4%.
What Smart Money Thinks
AbbVie's institutional ownership tilts toward dividend-quality active managers. T. Rowe Price holds 2.1%, Capital Group 1.9%, Wellington 1.4%. The notable additions in 2025–2026: Akre Capital initiated a 0.6M-share position in Q4/2025, citing 'the cleanest post-patent-cliff franchise transition in pharma history'; Polen Capital added 1.2M shares in Q1/2026. The 13F data shows a meaningful rotation toward AbbVie from generalist healthcare investors who had avoided the stock during the 2022–2024 Humira-cliff overhang.
The notable absence: Berkshire Hathaway has never held AbbVie. Buffett's pharma history (Sanofi 2007–2013, Teva 2017–2019) is mixed, and his current pharma exposure is minimal. The Berkshire-no-position is not a directional read.
Insider activity (Form 4): CEO Robert Michael (transitioned from Rick Gonzalez in July 2024) bought 8,500 shares in March 2026 at $195 — the first significant CEO open-market buy at AbbVie since Gonzalez's 2018 purchases. CFO Scott Reents purchased 2,500 shares in February. Two senior officer open-market buys at sub-$200 is the kind of insider-conviction signal that historically precedes outperformance.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The combined Skyrizi + Rinvoq Q1/2026 run-rate hit $30B (Skyrizi $16.8B + Rinvoq $12.8B annualized). Both products are still scaling: management guides to $40B+ combined by 2028. The patent runway is genuinely long — Skyrizi composition patent expires 2033 (with formulation patents to 2037), Rinvoq to 2035. By 2030, AbbVie has two Humira-scale franchises with 7+ years of remaining exclusivity each. The 2022–2026 Humira navigation has bought AbbVie another 10-year compounding window.
AbbVie's 3.4% dividend yield is among the highest in big pharma at quality scale. The dividend increase streak is 53 years (counting the Abbott Laboratories pre-spin years from 1972) — only Procter & Gamble (68 years), Coca-Cola (62 years), and Johnson & Johnson (63 years) have longer streaks in the S&P 500. The April 2026 dividend hike of 5.1% (to $1.65 quarterly) demonstrates capital-return discipline post-Humira-cliff. Combined dividend + 2% buyback yield = 5.4% baseline annual return.
AbbVie's forward P/E of 12.5 is the lowest among major pharma (Merck 12.4, Pfizer 11.2, BMS 7.8). But AbbVie's revenue growth (12.4%) is the highest among that peer set, and the Humira-cliff overhang is structurally resolved. The PEG ratio of ~1.0 is reasonable; the current discount to S&P 500 (forward P/E 23×) is roughly 45% — wider than fundamentally justified. A multiple rerating to 16–18× would imply a stock price of $250–$280, matching the upper-bound analyst targets.
📉 The 3 Real Bear Points
The Inflation Reduction Act's Medicare drug-price negotiation rules require 7 years of post-launch revenue before a drug becomes eligible. Skyrizi (launched 2019) becomes eligible in 2026 for 2028 negotiation pricing. Rinvoq (launched 2019) similar timeline. If both are selected for the 2028 negotiation list, the realized-pricing impact begins in 2029 at 20–25% below list. This could compress 2030 revenue by $4–$6B versus consensus — a meaningful headwind that the multiple does not currently price.
AbbVie's August 2024 acquisition of Cerevel Therapeutics for $8.7B added a portfolio of psychiatric and neurology pipeline assets (emraclidine for schizophrenia, tavapadon for Parkinson's). Emraclidine Phase 3 trial data is expected H2/2026; failure would mean the bulk of the $8.7B premium evaporates as goodwill impairment. Tavapadon is more durable but smaller commercial opportunity. The Cerevel valuation already prices Phase 3 success — failure compresses AbbVie stock 8–10%.
Humira biosimilar penetration eventually reached 65% (faster than initial 35% modeling). The same compressed-pricing dynamic is starting to apply to Stelara (JNJ) and could apply to Skyrizi when its biosimilars launch post-2033. The original AbbVie Humira-replacement model assumed Skyrizi would protect pricing through full patent life; the Stelara experience suggests biosimilar discounting may begin 12–18 months earlier than the patent cliff. If Skyrizi loses 10% of pricing in 2031–2032, the long-term valuation framework compresses.
Valuation in Context
AbbVie trades at a forward P/E of 12.5, EV/Sales of 6.0, and EV/EBITDA of 11.5 as of May 2026. Comparable big-pharma peers — Merck (forward P/E 12.4, EV/EBITDA 10.4), Pfizer (forward P/E 11.2, EV/EBITDA 9.1), Bristol-Myers Squibb (forward P/E 7.8, EV/EBITDA 6.8) — show AbbVie at peer-multiple despite materially better growth profile. The fundamental case: AbbVie deserves a 15–17× forward P/E based on the 12% revenue growth and the lower-than-modeled biosimilar erosion. Wall Street median price target $252.23 (24% upside), with dispersion from $184 (Bernstein, IRA-negotiation bear) to $328 (Cantor Fitzgerald, Skyrizi-extended-life bull). Sum-of-the-parts: Immunology (Skyrizi + Rinvoq + Humira-residual) at $115/share, Oncology (Imbruvica + Venclexta) at $40/share, Neuroscience (Vraylar + Cerevel pipeline) at $35/share, Aesthetics (Botox) at $22/share, Eye Care at $15/share — total $227/share, 12% upside.
🗓️ Next 3 Catalyst Dates
- July 31, 2026: Q2/2026 earnings — Skyrizi/Rinvoq combined run-rate trajectory toward the $40B 2028 target
- September 2026: Emraclidine Phase 3 readout — Cerevel acquisition validation; success unlocks $4B peak revenue line
- February 2027: CMS Medicare 2027 negotiation drug list announcement — Skyrizi/Rinvoq exposure clarifies
💬 Daniel's Take
AbbVie at $202 is the kind of position I genuinely consider holding for the long term. The Humira-to-Skyrizi/Rinvoq transition is the most underappreciated success story in big pharma — and the 12.5× forward P/E does not reflect that operational achievement. The Cerevel acquisition adds optionality (or risk, depending on the Phase 3 readout). The Robert Michael CEO transition + open-market insider buys at sub-$200 is meaningful conviction signal. My add-trigger is below $190 (sub-12× forward) which would happen on either an IRA-negotiation surprise or broader-pharma weakness. For dividend-focused portfolios with 5–10 year horizons, this is one of the best risk-adjusted pharma exposures — 3.4% yield + 8%+ EPS growth + multiple-rerating optionality = double-digit annualized returns realistic.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy AbbVie?
Compare top-rated brokers — low fees, trusted providers, fully regulated.